A Randomized Phase II-III Multicenter Trial of Docetaxel Plus Cisplatin and Docetaxel Plus 5-FU Versus Cisplatin Plus 5-FU in 1st Line Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
收藏DataCite Commons2025-02-06 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00001448/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
提供机构：
Vivli
创建时间：
2018-10-27
